期刊
VACCINE
卷 28, 期 9, 页码 2088-2096出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.12.038
关键词
Smallpox; Vaccinia; Mucosal vaccine; Tiantan; MVITZCI
资金
- Hong Kong research grant council [HK-RGC762208, HK-RGC762209]
- National Basic Research Program of China [2006CB504208]
- National 11th 5-year project [2008ZX10001-011]
- University Development Fund of the University of Hong Kong
To combat variola virus in bioterrorist attacks, it is desirable to develop a noninvasive vaccine. Based on the vaccinia Tiantan (VTT) strain, which was historically used to eradicate the smallpox in China, we generated a modified VTT (MVITZCI) by removing the hemagglutinin gene and an 11,944 bp genomic region from HindIII fragment C2L to F3L. MVTTZCI was characterized for its host cell range in vitro and preclinical safety and efficacy profiles in mice. Despite replication-competency in some cell lines, unlike VTT, MVTTZCI did not cause death after intracranial injection or body weight loss after intranasal inoculation. MVTTZCI did not replicate in mouse brain and was safe in immunodeficient mice. MVTTZCI induced neutralizing antibodies via the intranasal route of immunization. One time intranasal immunization protected animals from the challenge of the pathogenic vaccinia WR strain. This study established proof-of-concept that the attenuated replicating MVTTZCI may serve as a safe noninvasive smallpox vaccine candidate. (C) 2009 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据